The impact of reclassification by the 2022 ACR/EULAR classification criteria on risk factors for relapse in patients with ANCA-associated vasculitis
Open Access
- 7 September 2023
- journal article
- letter
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 16 (12) , 2754-2756
Abstract
No abstract availableFunding Information
- Dutch Kidney Foundation (17OKG04)
- Dutch Arthritis Foundation
- GlaxoSmithKline
- Aurinia Pharmaceuticals
- Vifor Pharma
This publication has 9 references indexed in Scilit:
- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 updateAnnals of the Rheumatic Diseases, 2023
- Validation of new ACR/EULAR 2022 classification criteria for anti-neutrophil cytoplasmic antibody–associated vasculitisModern Rheumatology, 2023
- Reclassification of previously diagnosed GPA patients using the 2022 ACR/EULAR classification criteriaRheumatology, 2022
- Application of the 2022 ACR/EULAR criteria for microscopic polyangiitis to patients with previously diagnosed microscopic polyangiitisClinical and Experimental Rheumatology, 2022
- 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitisAnnals of the Rheumatic Diseases, 2022
- 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with PolyangiitisAnnals of the Rheumatic Diseases, 2022
- ANCA-associated vasculitisNature Reviews Disease Primers, 2020
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisNew England Journal of Medicine, 2010
- Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic Antibody–Associated Small-Vessel VasculitisAnnals of Internal Medicine, 2005